Ignace Vergote und University Person-Info 

( Ich bin Ignace Vergote)
(1 - 27 von 28
)

Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in...

www.globenewswire.com
The study, referred to as the SIGN Study, is being led by Ignace Vergote, MD, at the University Hospitals, Leuven, Belgium. SIGN is also open at ...
+1